Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Cash & Equivalents (2018 - 2025)

Outset Medical (OM) has disclosed Cash & Equivalents for 8 consecutive years, with $35.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 71.77% to $35.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.0 million through Dec 2025, down 71.77% year-over-year, with the annual reading at $35.0 million for FY2025, 71.77% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $35.0 million at Outset Medical, down from $36.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $274.3 million in Q2 2021, with the low at $35.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $102.8 million, with a median of $73.7 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 72.47% in 2022, then soared 354.99% in 2025.
  • Over 5 years, Cash & Equivalents stood at $215.7 million in 2021, then plummeted by 64.51% to $76.5 million in 2022, then decreased by 6.13% to $71.8 million in 2023, then surged by 72.63% to $124.0 million in 2024, then plummeted by 71.77% to $35.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $35.0 million, $36.4 million, and $187.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.